Familial Hypophosphatemia and Related Disorders

Ingrid A. Holm, Michael Econs, Thomas O. Carpenter

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

This chapter provides a detailed overview of the prototype hypophosphatemic disease, XLH. Novel and established clinical features of XLH are reviewed. Key elements central to the pathophysiology of XLH and its related disorders are discussed, including the putative function of the mutated endopeptidase PHEX. The biochemistry of FGF-23 is reviewed with respect to its role in the related disorder, autosomal dominant hypophosphatemic rickets (ADHR). Clinical features of related disorders including ADHR, hereditary hypophosphatemic rickets with hypercalciuria (HHRH), and tumor-induced osteomalacia (TIO) are compared to those observed in XLH. XLH is one of the most common bone diseases seen in children, with available therapies that only partially address the long-term morbidity of the condition. These suboptimal therapeutic approaches require frequent biochemical monitoring, and the panoply of chronic features that complicate the condition persist throughout life. XLH is characterized by renal phosphate wasting leading to hypophosphatemia and low or normal concentrations of 1,25-dihydroxyvitamin D (1,25(OH)2D), an inappropriate response to hypophosphatemia. In children, the disorder first becomes apparent with the development of rickets, skeletal deformities, short stature, and dental abscesses. In adults, manifestations of XLH include osteomalacia, degenerative joint disease, enthesopathy, bone and joint pain, and continued dental disease.

Original languageEnglish
Title of host publicationPediatric Bone
PublisherElsevier Inc.
Pages699-726
Number of pages28
ISBN (Print)9780123820402
DOIs
StatePublished - 2012

Fingerprint

Familial Hypophosphatemia
Hypophosphatemia
Stomatognathic Diseases
Osteomalacia
Endopeptidases
Rickets
Bone Diseases
Arthralgia
Osteoarthritis
Biochemistry
Abscess
Tooth
Phosphates
Morbidity
Kidney
Bone and Bones
Therapeutics
Autosomal Dominant Hypophosphatemic Rickets

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Holm, I. A., Econs, M., & Carpenter, T. O. (2012). Familial Hypophosphatemia and Related Disorders. In Pediatric Bone (pp. 699-726). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-382040-2.10026-7

Familial Hypophosphatemia and Related Disorders. / Holm, Ingrid A.; Econs, Michael; Carpenter, Thomas O.

Pediatric Bone. Elsevier Inc., 2012. p. 699-726.

Research output: Chapter in Book/Report/Conference proceedingChapter

Holm, IA, Econs, M & Carpenter, TO 2012, Familial Hypophosphatemia and Related Disorders. in Pediatric Bone. Elsevier Inc., pp. 699-726. https://doi.org/10.1016/B978-0-12-382040-2.10026-7
Holm IA, Econs M, Carpenter TO. Familial Hypophosphatemia and Related Disorders. In Pediatric Bone. Elsevier Inc. 2012. p. 699-726 https://doi.org/10.1016/B978-0-12-382040-2.10026-7
Holm, Ingrid A. ; Econs, Michael ; Carpenter, Thomas O. / Familial Hypophosphatemia and Related Disorders. Pediatric Bone. Elsevier Inc., 2012. pp. 699-726
@inbook{d9ad7a1dd30d468898bc5643502594fa,
title = "Familial Hypophosphatemia and Related Disorders",
abstract = "This chapter provides a detailed overview of the prototype hypophosphatemic disease, XLH. Novel and established clinical features of XLH are reviewed. Key elements central to the pathophysiology of XLH and its related disorders are discussed, including the putative function of the mutated endopeptidase PHEX. The biochemistry of FGF-23 is reviewed with respect to its role in the related disorder, autosomal dominant hypophosphatemic rickets (ADHR). Clinical features of related disorders including ADHR, hereditary hypophosphatemic rickets with hypercalciuria (HHRH), and tumor-induced osteomalacia (TIO) are compared to those observed in XLH. XLH is one of the most common bone diseases seen in children, with available therapies that only partially address the long-term morbidity of the condition. These suboptimal therapeutic approaches require frequent biochemical monitoring, and the panoply of chronic features that complicate the condition persist throughout life. XLH is characterized by renal phosphate wasting leading to hypophosphatemia and low or normal concentrations of 1,25-dihydroxyvitamin D (1,25(OH)2D), an inappropriate response to hypophosphatemia. In children, the disorder first becomes apparent with the development of rickets, skeletal deformities, short stature, and dental abscesses. In adults, manifestations of XLH include osteomalacia, degenerative joint disease, enthesopathy, bone and joint pain, and continued dental disease.",
author = "Holm, {Ingrid A.} and Michael Econs and Carpenter, {Thomas O.}",
year = "2012",
doi = "10.1016/B978-0-12-382040-2.10026-7",
language = "English",
isbn = "9780123820402",
pages = "699--726",
booktitle = "Pediatric Bone",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Familial Hypophosphatemia and Related Disorders

AU - Holm, Ingrid A.

AU - Econs, Michael

AU - Carpenter, Thomas O.

PY - 2012

Y1 - 2012

N2 - This chapter provides a detailed overview of the prototype hypophosphatemic disease, XLH. Novel and established clinical features of XLH are reviewed. Key elements central to the pathophysiology of XLH and its related disorders are discussed, including the putative function of the mutated endopeptidase PHEX. The biochemistry of FGF-23 is reviewed with respect to its role in the related disorder, autosomal dominant hypophosphatemic rickets (ADHR). Clinical features of related disorders including ADHR, hereditary hypophosphatemic rickets with hypercalciuria (HHRH), and tumor-induced osteomalacia (TIO) are compared to those observed in XLH. XLH is one of the most common bone diseases seen in children, with available therapies that only partially address the long-term morbidity of the condition. These suboptimal therapeutic approaches require frequent biochemical monitoring, and the panoply of chronic features that complicate the condition persist throughout life. XLH is characterized by renal phosphate wasting leading to hypophosphatemia and low or normal concentrations of 1,25-dihydroxyvitamin D (1,25(OH)2D), an inappropriate response to hypophosphatemia. In children, the disorder first becomes apparent with the development of rickets, skeletal deformities, short stature, and dental abscesses. In adults, manifestations of XLH include osteomalacia, degenerative joint disease, enthesopathy, bone and joint pain, and continued dental disease.

AB - This chapter provides a detailed overview of the prototype hypophosphatemic disease, XLH. Novel and established clinical features of XLH are reviewed. Key elements central to the pathophysiology of XLH and its related disorders are discussed, including the putative function of the mutated endopeptidase PHEX. The biochemistry of FGF-23 is reviewed with respect to its role in the related disorder, autosomal dominant hypophosphatemic rickets (ADHR). Clinical features of related disorders including ADHR, hereditary hypophosphatemic rickets with hypercalciuria (HHRH), and tumor-induced osteomalacia (TIO) are compared to those observed in XLH. XLH is one of the most common bone diseases seen in children, with available therapies that only partially address the long-term morbidity of the condition. These suboptimal therapeutic approaches require frequent biochemical monitoring, and the panoply of chronic features that complicate the condition persist throughout life. XLH is characterized by renal phosphate wasting leading to hypophosphatemia and low or normal concentrations of 1,25-dihydroxyvitamin D (1,25(OH)2D), an inappropriate response to hypophosphatemia. In children, the disorder first becomes apparent with the development of rickets, skeletal deformities, short stature, and dental abscesses. In adults, manifestations of XLH include osteomalacia, degenerative joint disease, enthesopathy, bone and joint pain, and continued dental disease.

UR - http://www.scopus.com/inward/record.url?scp=84882810295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882810295&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-382040-2.10026-7

DO - 10.1016/B978-0-12-382040-2.10026-7

M3 - Chapter

AN - SCOPUS:84882810295

SN - 9780123820402

SP - 699

EP - 726

BT - Pediatric Bone

PB - Elsevier Inc.

ER -